Kyowa Kirin Pharmaceutical Research, Inc.

73 articles about Kyowa Kirin Pharmaceutical Research, Inc.

• Kyowa Hakko Kirin to Sell Chemical Unit for up to $720 Million; Potential Buyers Asked to Submit Initial Bids

  10/6/2010

• H. Lundbeck A/S Enters Into License Agreement With Kyowa Hakko Kirin For A2a Antagonists For Parkinson's and Other Indications

  10/6/2010

• ArQule, Inc. Announces Initiation by Kyowa Hakko Kirin of Phase 2 Clinical Trial in Asia with ARQ 197 in Gastric Cancer

  7/28/2010

• Biovail Corporation to Pay Kyowa Hakko Kirin up to $65 Million for U.S., Canadian Rights to Parkinson's Drug

  6/3/2010

• Solasia Pharma K.K. and Kyowa Hakko Kirin Enter Into a License Agreement for SP-01 (Sancuso(R)) in Asia

  3/3/2010

• Orexo AB Announces That Partner Kyowa Hakko Kirin Entered a Joint Distribution Agreement on KW-2246 for Treatment of Cancer Pain in Japan

  2/2/2010

• Reata Pharmaceuticals, Inc. Licenses Chronic Kidney Disease Drug Bardoxolone Methyl to Kyowa Hakko Kirin in $272 Million Deal

  1/8/2010

• Orexo AB Announces Kyowa Hakko Kirin Receives Positive Phase III Results for KW-2246 in Japan

  7/24/2009

• Kyowa Hakko Kirin Fiscal 2008 Sales up 17.4%, Operating Income up 15.2%

  4/28/2009

• Kyowa Hakko Kirin Third Quarter Results; Revision of Full Year Forecasts; Planned Change of Fiscal Year End

  1/30/2009

• Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline)

  1/15/2009

• Kyowa Hakko Kirin Interim Results

  10/30/2008

• Kyowa Hakko Kirin Revises Down Profit Forecasts: Full Year Sales Forecast Unchanged

  10/21/2008